Atopic Dermatitis
Conditions
Interventions
The anti-Staphylococcus aureus ostrich antibody emulsion will be put the target lesion over on the left side and placebo emulsion will be put the target lesion over on the right side, per two palms wi
Sponsors
Miyagawa Fumi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with atopic dermatitis receiving therapy with dupilumab for 16 weeks 2) Patients who having treatment-resistant bisymmetric lesion evaluated the same grade severity (four categories: mild, moderate, severe, most severe) with Eczema Area and Severity Index (EASI) score in local lesion 3) Patients who are 18 years old and more at informed consent 4) Patients who is eligible to agree with consent form
Exclusion criteria
Exclusion criteria: 1)Patients determined ineligible to participate by principal investigator or sub investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rates of change from baseline to 4 weeks after started the treatment at Eczema Area and Severity Index (EASI) score in local lesion | — |
Secondary
| Measure | Time frame |
|---|---|
| Rates of change from baseline to 2 weeks after started the treatment at EASI score in local lesion. Points of change from baseline to 2 or 4 weeks after started the treatment at Numerical Rating Scale score. Points of change from baseline to 2 or 4 weeks after started the treatment at The Patient Oriented Eczema Measure score. | — |
Contacts
Public ContactFumi Miyagawa
Nara Medical University Hospital
Outcome results
None listed